<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun J Sanyal, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H417351900"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The portal vein is formed by the confluence of the splenic and superior mesenteric veins, which drain the spleen and small intestine, respectively  (<a class="graphic graphic_figure graphicRef68680" href="/z/d/graphic/68680.html" rel="external">figure 1</a>). Occlusion of the portal vein by thrombus (portal vein thrombosis [PVT]) typically occurs in patients with cirrhosis and/or prothrombotic disorders  (<a class="graphic graphic_table graphicRef73799" href="/z/d/graphic/73799.html" rel="external">table 1</a>). Patients with acute PVT have the sudden onset of portal venous occlusion due to thrombus. The occlusion may be complete or partial. In addition to involving the portal vein, the clot may also involve the mesenteric veins or the splenic vein. Patients with acute PVT have not yet developed features of chronic PVT, such as collateral circulation (eg, cavernous portal transformation) or portal hypertension. If it is not known when the clot developed, but the patient does not have features of chronic PVT, the PVT can be referred to as being "recent" [<a href="#rid1">1</a>]. Patients with recent PVT are managed the same as those with acute PVT.</p><p>This topic will review the clinical manifestations, diagnosis, and management of acute PVT. The epidemiology and pathogenesis of PVT, as well as the approach to patients with chronic PVT are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p>The approach to patients with PVT has also been reviewed in society guidelines [<a href="#rid2">2-4</a>]. The discussion that follows is generally consistent with those guidelines.</p><p class="headingAnchor" id="H57741437"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of acute portal vein thrombosis (PVT) depend on the extent of the obstruction and the speed of its development. </p><p class="headingAnchor" id="H64328633"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Acute PVT may be clinically silent and diagnosed during a radiologic examination for other reasons (such as acute pancreatitis)  (<a class="graphic graphic_diagnosticimage graphicRef78815" href="/z/d/graphic/78815.html" rel="external">image 1</a>). Other patients may have abdominal pain that develops suddenly or progresses over a few days [<a href="#rid5">5</a>]. Patients may also report fever and dyspeptic symptoms. Patients with cirrhosis may present with variceal bleeding. The presence of spiking fevers, chills, and a painful liver is suggestive of septic PVT (acute pylephlebitis). In addition to symptoms related to the PVT, patients may also have symptoms related to conditions that predispose to the development of PVT, such as acute pancreatitis. (See  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Clinical manifestations'</a>.)</p><p>If the superior mesenteric vein is occluded, patients may have colicky abdominal pain and diarrhea [<a href="#rid5">5</a>]. If the proximal mesenteric venous arches are involved, ischemia and ultimately infarction may develop. In such patients, the abdominal pain may radiate to the back, persist beyond five to seven days, be associated with abdominal distension from ascites, and be associated with bloody diarrhea. For some patients with underlying inflammatory bowel disease, the clinical presentation of acute PVT (eg, abdominal pain, diarrhea) may mimic a disease flare.</p><p class="headingAnchor" id="H64328640"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Most patients with acute PVT do not have abnormal findings on physical examination. However, some patients with acute PVT may have an ileus and thus have abdominal distension without other signs of intestinal obstruction [<a href="#rid5">5</a>]. Patients typically do not have guarding unless the PVT is the result of an intra-abdominal inflammatory process or if intestinal infarction has occurred. Patients with infarction may also have signs of ascites on examination (eg, a fluid wave). Patients with cirrhosis may have stigmata of chronic liver disease, such as palmar erythema, or signs of hepatic encephalopathy. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Physical examination'</a> and  <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H64328647"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing may reveal elevations in plasma levels of acute phase reactants (sometimes markedly elevated). Liver tests are typically normal because hepatic arterial blood flow compensates for decreased portal inflow, although a transient, moderate increase in serum aminotransferases is seen in some patients. In patients with bowel ischemia, laboratory testing may reveal metabolic acidosis, signs of renal or respiratory failure, a leukocytosis, and an elevated hematocrit due to hemoconcentration [<a href="#rid5">5</a>]. In patients with septic PVT, blood cultures are often positive for <em>Bacteroides fragilis</em> or <em>Escherichia coli, </em>although other pathogens have also been cultured. In patients with cirrhosis, laboratory testing may reveal an elevated bilirubin, low platelet count, prolonged international normalized ratio (INR), or renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Laboratory findings'</a> and  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults", section on 'Laboratory studies'</a>.)</p><p class="headingAnchor" id="H64328683"><span class="h2">Abdominal imaging</span><span class="headingEndMark"> — </span>Patients with acute PVT who undergo abdominal imaging have evidence of portal venous occlusion and may have findings suggestive of intestinal ischemia. In addition, imaging may reveal an underlying focus of infection or multiple, small liver abscesses in patients with septic PVT. (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Imaging studies'</a>.)</p><p class="headingAnchor" id="H57741474"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Acute portal vein thrombosis (PVT) is diagnosed with abdominal imaging that demonstrates portal venous occlusion without the radiographic findings of chronic PVT (eg, cavernous portal transformation). (See  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management", section on 'Diagnosis'</a>.)</p><p>In patients with suspected acute PVT, we typically obtain a contrast-enhanced abdominal computed tomography (CT) to confirm the diagnosis, evaluate for predisposing conditions (eg, intra-abdominal infection), assess the extent of the thrombosis and the anatomy of collaterals, and detect evidence of intestinal infarction  (<a class="graphic graphic_table graphicRef73799" href="/z/d/graphic/73799.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults", section on 'Epidemiology'</a>.)</p><p>If suspicion for PVT is not high (eg, the patient does not have cirrhosis or other risk factors for thrombosis), a Doppler ultrasound is a reasonable initial approach. If the ultrasound suggests acute PVT, an abdominal CT can then be obtained. (See  <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults", section on 'Epidemiology'</a>.)</p><p>Abdominal magnetic resonance imaging (MRI) is an alternative in patients who cannot undergo CT or in whom radiation exposure from CT is a concern. If CT and MRI are contraindicated or not available, ultrasound with Doppler is an alternative, although ultrasound may not detect predisposing conditions or ischemia. Finally, a diagnosis of PVT can be made with portal venography or superior mesenteric angiography, but angiography is invasive and is generally not required [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H406033994"><span class="h2">Abdominal CT or MRI</span><span class="headingEndMark"> — </span>In patients with acute PVT, a CT scan without contrast may show hyperattenuating material in the portal vein, though contrast-enhanced imaging is often needed to make the diagnosis because the density of the thrombus may be difficult to differentiate from the vessel wall [<a href="#rid7">7-9</a>]. Imaging after injecting intravenous contrast may reveal lack of luminal enhancement, increased hepatic enhancement in the arterial phase, and decreased hepatic enhancement in the portal phase [<a href="#rid10">10,11</a>]. On MRI angiography, PVT appears as a filling defect that partially or completely occludes the vessel lumen in the portal venous phase [<a href="#rid12">12</a>]. Data are lacking on the sensitivity and specificity of CT and MRI for detecting PVT. In a study with 36 patients, MRI had a sensitivity of 100 percent and a specificity of 99 percent for detecting PVT [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H64328776"><span class="h2">Abdominal ultrasound with Doppler</span><span class="headingEndMark"> — </span>Abdominal ultrasonography in patients with acute PVT may show hyperechoic material within the portal vein, with distension of the portal vein and its tributaries [<a href="#rid14">14</a>]. The portal vein diameter is typically greater than 13 to 55 mm in diameter and does not vary in diameter during respiration [<a href="#rid7">7</a>]. Because a thrombus may not be visualized on ultrasound in up to a third of patients with PVT, Doppler imaging should also be used. In patients with PVT, Doppler imaging will show the absence of flow in some or all of the vessel lumen. Ultrasonography with Doppler imaging has been estimated to be 89 to 93 percent sensitive and 92 to 93 percent specific for diagnosing PVT [<a href="#rid10">10,15</a>]. The accuracy of Doppler ultrasound depends in part on the expertise of the ultrasonographer and whether PVT was suspected prior to the examination [<a href="#rid5">5,16</a>]. The sensitivity of Doppler ultrasound for PVT may be increased by adding contrast-enhancing agents [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H406033910"><span class="h2">Identification of predisposing conditions</span><span class="headingEndMark"> — </span>Patients with PVT who do not have cirrhosis or who have compensated (Child class A or B) cirrhosis should be evaluated for conditions that may have predisposed to thrombosis, such as prothrombotic states. Because PVT is common in patients with decompensated cirrhosis, it is reasonable not to pursue an evaluation for other predisposing conditions in such patients. The approach to the evaluation of patients with established venous thrombosis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H57741482"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The primary considerations in the differential diagnosis of acute portal vein thrombosis (PVT) are invasion of the portal vein by an abdominal malignancy (most frequently hepatocellular carcinoma) or, less often, constriction of the portal vein within a tumor (typically pancreatic cancer or cholangiocarcinoma) [<a href="#rid5">5</a>]. In cases of tumor invasion or external constriction, a thrombus within the portal vein may develop as a secondary event (malignant PVT). Imaging characteristics can help differentiate benign PVT from malignant PVT. Differentiating benign from malignant PVT is particularly important in patients with cirrhosis and hepatocellular carcinoma who are being considered for liver transplantation since malignant PVT is a contraindication to liver transplantation. </p><p>Findings that suggest a malignant PVT include [<a href="#rid18">18,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated alpha fetoprotein</p><p class="bulletIndent1"><span class="glyph">●</span>Portal vein diameter &gt;23 mm</p><p class="bulletIndent1"><span class="glyph">●</span>Enhancement of endoluminal material during the arterial phase of contrast injection</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial-like pulsatile flow seen with Doppler ultrasound</p><p class="bulletIndent1"><span class="glyph">●</span>Disruption of the vessel walls or tumor encroaching on the portal vein</p><p></p><p class="headingAnchor" id="H57741452"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The primary management of acute portal vein thrombosis (PVT) is anticoagulation and, when possible, treatment of predisposing conditions  (<a class="graphic graphic_table graphicRef73799" href="/z/d/graphic/73799.html" rel="external">table 1</a>). The goal of anticoagulation is to prevent extension of the clot and to allow for recanalization so that intestinal infarction and portal hypertension do not develop. Unlike chronic PVT, where the role of anticoagulation in patients with cirrhosis is unclear, studies suggest anticoagulation for acute PVT is beneficial for patients with cirrhosis. However, because patients with cirrhosis may have esophageal varices, we typically screen for varices prior to initiating anticoagulation. (See <a class="local">'Efficacy of anticoagulation'</a> below and  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management", section on 'Anticoagulation'</a>.)</p><p>Patients should be started on low molecular weight heparin to achieve rapid anticoagulation, with a switch to an oral anticoagulant (<a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or possibly a direct-acting oral anticoagulant [DOAC]) once the patient's condition has stabilized and no invasive procedures are planned (if warfarin is used, our goal international normalized ratio [INR] is 2 to 3) [<a href="#rid5">5</a>]. The role and safety of anticoagulation in patients with cirrhosis and severe liver dysfunction is not well established, but studies indicate that the outcomes for patients with acute PVT are not worse compared with patients without thrombosis [<a href="#rid20">20</a>]. </p><p>Data from mostly observational studies have indicated that direct oral anticoagulants may also be used to treat PVT successfully [<a href="#rid21">21-24</a>]. However, for patients with cirrhosis, there are reports suggesting decreased efficacy of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> [<a href="#rid25">25</a>]. In addition, one small retrospective series suggested that the bleeding risks with these agents are comparable to those seen with traditional anticoagulation [<a href="#rid26">26</a>]. More data are needed to make evidence-based recommendations on the use of these agents in patients with acute PVT, particularly for those with cirrhosis. </p><p>Treatment is generally recommended for at least three to six months, though long-term treatment is recommended for most patients with permanent thrombotic risk factors that cannot be corrected [<a href="#rid2">2,4</a>]. Long-term therapy may also be appropriate for patients with acute PVT that extends into the mesenteric veins, given the risk of intestinal infarction in such patients. In patients with cirrhosis, non-warfarin-based therapy may be preferable since the INR may not reflect the patient's level of anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Portal vein thrombosis (PVT)'</a>.)</p><p>In addition to anticoagulation, patients with septic PVT require antibiotic therapy. Patients who develop infarction in the setting of acute PVT require surgical exploration. Failure to do so is associated with high mortality rates. (See  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H235138178"><span class="h2">Efficacy of anticoagulation</span><span class="headingEndMark"> — </span>The use of anticoagulation in patients with acute PVT is supported by studies that suggest it leads to increased recanalization rates of the portal vein compared with no treatment. Recanalization is important because failure to restore venous drainage of the small intestine puts patients at risk for intestinal ischemia and infarction, as well as complications from chronic PVT. In addition, the use of anticoagulation for acute PVT is indirectly supported by numerous trials that show a benefit of anticoagulation patients with deep vein thrombosis. (See  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p>Limited data suggest that patients diagnosed with acute PVT are unlikely to spontaneously recanalize their portal vein [<a href="#rid1">1,27,28</a>]. However, retrospective studies have found that if patients are treated with anticoagulation, at least partial recanalization of the portal vein occurs in 63 to 93 percent of patients, with complete recanalization in 34 to 45 percent [<a href="#rid1">1,27-30</a>]. As an example, in a series of 95 patients with acute PVT followed for a median of 234 days, anticoagulation restored patency of the portal vein in 39 percent of patients. Failure to recanalize the portal vein was independently associated with the presence of ascites or an occluded splenic vein [<a href="#rid27">27</a>]. </p><p>Anticoagulation also appears to be beneficial for patients with acute PVT in the setting of cirrhosis. In a series of 55 patients with cirrhosis and acute or recent PVT who received anticoagulation, 33 (60 percent) achieved partial or complete recanalization, with complete recanalization occurring in 25 (45 percent) [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Portal vein thrombosis (PVT)'</a>.)</p><p class="headingAnchor" id="H235138193"><span class="h2">Duration of anticoagulation</span><span class="headingEndMark"> — </span>Our approach is to treat patients with anticoagulation for six months provided there is no indication for long-term anticoagulation, such as a permanent thrombotic risk factor that cannot be corrected or a thrombus that extends into the mesenteric veins. If recanalization occurs, it typically does so within six months of starting anticoagulation [<a href="#rid29">29,32</a>]. In patients who do not have an indication for life-long therapy, such as an underlying hypercoagulable state, it is not clear whether to continue anticoagulation beyond six months if complete recanalization has not occurred by that time. Our practice is to discontinue anticoagulation after six months in such patients. We continue to monitor patients for recurrence of symptoms (eg, abdominal pain), and we repeat imaging in three months after discontinuing anticoagulation.</p><p class="headingAnchor" id="H235138209"><span class="h2">Complications of anticoagulation</span><span class="headingEndMark"> — </span>Anticoagulation may lead to bleeding in some patients. Studies in patients with acute PVT who do not have cirrhosis have reported bleeding rates of 0 to 6 percent (often minor bleeding, but sometimes severe) [<a href="#rid1">1,28-30</a>]. The risk may be higher in patients with cirrhosis. In a study of 55 patients with cirrhosis and acute PVT who were treated with anticoagulation, five (9 percent) developed bleeding [<a href="#rid31">31</a>]. Bleeding was more common among patients with a platelet count less than 50,000. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a>.)</p><p class="headingAnchor" id="H235138201"><span class="h2">Alternatives to anticoagulation</span><span class="headingEndMark"> — </span>Several case reports have documented successful lysis of acute PVT using streptokinase or tissue plasminogen activator administered locally by a catheter passed via a transjugular transhepatic or percutaneous transhepatic route [<a href="#rid33">33-38</a>]. In a systematic review that included 71 patients undergoing thrombolysis (with or without thrombectomy), recanalization of the portal vein was complete in 29 patients (41 percent), partial in 32 (45 percent), and absent in 10 (14 percent) [<a href="#rid37">37</a>]. However, the benefit of this approach is uncertain, since the natural history of this condition is not well defined. In addition, serious complications have been reported including significant bleeding and death [<a href="#rid37">37</a>]. In one study, 12 of 20 patients (60 percent) had major complications [<a href="#rid38">38</a>].</p><p>Another alternative to anticoagulation is surgical thrombectomy. It is typically reserved for patients who are undergoing surgery for intestinal infarction. In such patients, surgical thrombectomy can be carried out during the laparotomy.</p><p class="headingAnchor" id="H62356949"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>If treatment for acute portal vein thrombosis (PVT) is initiated prior to the onset of intestinal infarction, the patient's prognosis is good [<a href="#rid1">1,39-43</a>]. Abdominal pain and systemic inflammatory response syndrome will start to subside within hours to days after the initiation of anticoagulation and intestinal infarction is prevented if the superior mesenteric vein remains patent or recanalizes. In addition, portal hypertension is prevented if the portal trunk and at least one of its branches remains patent or is recanalized. In a prospective study of 105 patients with acute PVT, 44 percent achieved patency of portal venous flow, with a mortality rate of 2 percent at one year [<a href="#rid44">44</a>].</p><p>Untreated, patients with acute PVT may develop intestinal infarction, though the frequency with which this occurs is unclear. Infarction leads to intestinal perforation, peritonitis, shock, multiorgan failure, and death if treatment is not provided promptly [<a href="#rid45">45</a>]. </p><p>Acute PVT may become chronic among patients who do not develop intestinal ischemia and who do not receive treatment (eg, patients with asymptomatic acute PVT). Limited data suggest that patients diagnosed with acute PVT who do not receive treatment with anticoagulation therapy rarely have spontaneous recanalization of the portal vein [<a href="#rid1">1,27,28</a>]. However, it is not known how often patients with acute PVT who do not come to medical attention spontaneously recanalize. </p><p class="headingAnchor" id="H2882190052"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119173.html" rel="external">"Society guideline links: Hepatic, portal, and splenic vein thrombosis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Patients with acute portal vein thrombosis (PVT) have the sudden onset of portal venous occlusion due to thrombus. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Acute PVT may be clinically silent or patients may report symptoms such as abdominal pain that develops suddenly or progresses over a few days. Patients with cirrhosis may present with variceal bleeding. The presence of spiking fevers, chills, and a painful liver is suggestive of septic PVT (acute pylephlebitis). Intestinal infarction should be considered in patients who have abdominal pain that radiates to the back, persists beyond five to seven days, is associated with abdominal distension, or is associated with bloody diarrhea. (See <a class="local">'Clinical manifestations'</a> above and  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation </strong>– In patients with suspected acute PVT, our initial approach is to obtain a contrast-enhanced abdominal computed tomographic (CT) scan or Doppler ultrasound. In addition to confirming the diagnosis of acute PVT, CT can identify potential predisposing conditions (eg, intra-abdominal infection), assess the extent of the thrombosis, and detect evidence of intestinal infarction. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Patients with PVT who do not have cirrhosis or who have compensated (Child A or B) cirrhosis should be evaluated for conditions that may have predisposed to the development of the clot, such as prothrombotic states. Because PVT is common in patients with decompensated cirrhosis, it is reasonable not to pursue an evaluation in such patients unless they also have a history of thrombotic episodes at another location or other clinical clues suggestive of a hypercoagulable state. (See <a class="local">'Identification of predisposing conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– We recommend anticoagulation therapy for patients with acute portal vein thrombosis rather than expectant management, provided that there is no excessive bleeding risk (eg, large esophageal varices) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In addition, when possible, predisposing conditions should be treated. Patients should be started on low molecular weight heparin to achieve rapid anticoagulation, with a switch to an oral anticoagulant once the patient's condition has stabilized and no invasive procedures are planned (if <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is used, our goal international normalized ratio is 2 to 3). In patients with cirrhosis, non-warfarin-based therapy may be preferable since the INR may not reflect the patient's level of anticoagulation. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">For patients with transient or correctable thrombotic risk factors (eg, pancreatitis) or in whom no thrombotic risk factor is identified, we suggest six months of anticoagulation rather than long-term anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with permanent thrombotic risk factors that cannot be corrected, we suggest long-term anticoagulation rather than six months anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, long-term therapy may also be appropriate for patients with acute PVT that extends into the mesenteric veins, given the risk of intestinal infarction in such patients. (See <a class="local">'Duration of anticoagulation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="96f3f7e5faf9f0f0fff5f3d6f3f7e5faf9f0f0fff5f3b8f3e3">[email protected]</span>. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.</a></li><li><a class="nounderline abstract_t">Simonetto DA, Singal AK, Garcia-Tsao G, et al. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol 2020; 115:18.</a></li><li><a class="nounderline abstract_t">Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73:366.</a></li><li><a class="nounderline abstract_t">Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42:163.</a></li><li><a class="nounderline abstract_t">Subramanyam BR, Balthazar EJ, Lefleur RS, et al. Portal venous thrombosis: correlative analysis of sonography, CT and angiography. Am J Gastroenterol 1984; 79:773.</a></li><li><a class="nounderline abstract_t">Hidajat N, Stobbe H, Griesshaber V, et al. Imaging and radiological interventions of portal vein thrombosis. Acta Radiol 2005; 46:336.</a></li><li><a class="nounderline abstract_t">Marn CS, Francis IR. CT of portal venous occlusion. AJR Am J Roentgenol 1992; 159:717.</a></li><li><a class="nounderline abstract_t">Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol 2022; 12:965.</a></li><li><a class="nounderline abstract_t">Bach AM, Hann LE, Brown KT, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201:149.</a></li><li><a class="nounderline abstract_t">Mathieu D, Vasile N, Grenier P. Portal thrombosis: dynamic CT features and course. Radiology 1985; 154:737.</a></li><li><a class="nounderline abstract_t">Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010; 254:154.</a></li><li><a class="nounderline abstract_t">Kreft B, Strunk H, Flacke S, et al. Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography. Radiology 2000; 216:86.</a></li><li><a class="nounderline abstract_t">Van Gansbeke D, Avni EF, Delcour C, et al. Sonographic features of portal vein thrombosis. AJR Am J Roentgenol 1985; 144:749.</a></li><li><a class="nounderline abstract_t">Tessler FN, Gehring BJ, Gomes AS, et al. Diagnosis of portal vein thrombosis: value of color Doppler imaging. AJR Am J Roentgenol 1991; 157:293.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156:1582.</a></li><li><a class="nounderline abstract_t">Marshall MM, Beese RC, Muiesan P, et al. Assessment of portal venous system patency in the liver transplant candidate: a prospective study comparing ultrasound, microbubble-enhanced colour Doppler ultrasound, with arteriography and surgery. Clin Radiol 2002; 57:377.</a></li><li><a class="nounderline abstract_t">Piscaglia F, Gianstefani A, Ravaioli M, et al. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl 2010; 16:658.</a></li><li><a class="nounderline abstract_t">Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168:719.</a></li><li><a class="nounderline abstract_t">Levi Sandri GB, Lai Q, Berloco PB, Rossi M. Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival. Exp Clin Transplant 2014; 12:238.</a></li><li><a class="nounderline abstract_t">Pannach S, Babatz J, Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost 2013; 110:626.</a></li><li><a class="nounderline abstract_t">Lenz K, Dieplinger B, Buder R, et al. Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 2014; 52:1175.</a></li><li><a class="nounderline abstract_t">Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 2019; 113:86.</a></li><li><a class="nounderline abstract_t">Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 2020; 4:655.</a></li><li><a class="nounderline abstract_t">Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology 2015; 61:1435.</a></li><li><a class="nounderline abstract_t">Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016; 61:1721.</a></li><li><a class="nounderline abstract_t">Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51:210.</a></li><li><a class="nounderline abstract_t">Turnes J, García-Pagán JC, González M, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008; 6:1412.</a></li><li><a class="nounderline abstract_t">Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007; 102:2464.</a></li><li><a class="nounderline abstract_t">Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 2007; 7:34.</a></li><li><a class="nounderline abstract_t">Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10:776.</a></li><li><a class="nounderline abstract_t">Martinelli I, Primignani M, Aghemo A, et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol 2009; 50:916.</a></li><li><a class="nounderline abstract_t">Blum U, Haag K, Rössle M, et al. Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. Radiology 1995; 195:153.</a></li><li><a class="nounderline abstract_t">Cherukuri R, Haskal ZJ, Naji A, Shaked A. Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up. Transplantation 1998; 65:1124.</a></li><li><a class="nounderline abstract_t">Hänig V, Stenzel G, Rössle M. [Acute portal vein thrombosis in liver cirrhosis: successful recanalization with the use of a portosystemic shunt (TIPS)]. Rofo 1996; 165:403.</a></li><li><a class="nounderline abstract_t">Mann O, Haag K, Hauenstein KH, et al. [Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)]. Dtsch Med Wochenschr 1995; 120:1201.</a></li><li><a class="nounderline abstract_t">Hall TC, Garcea G, Metcalfe M, et al. Management of acute non-cirrhotic and non-malignant portal vein thrombosis: a systematic review. World J Surg 2011; 35:2510.</a></li><li><a class="nounderline abstract_t">Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:651.</a></li><li><a class="nounderline abstract_t">Baril N, Wren S, Radin R, et al. The role of anticoagulation in pylephlebitis. Am J Surg 1996; 172:449.</a></li><li><a class="nounderline abstract_t">Sheen CL, Lamparelli H, Milne A, et al. Clinical features, diagnosis and outcome of acute portal vein thrombosis. QJM 2000; 93:531.</a></li><li><a class="nounderline abstract_t">Lagasse JP, Bahallah ML, Salem N, et al. [Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients]. Gastroenterol Clin Biol 1997; 21:919.</a></li><li><a class="nounderline abstract_t">Grisham A, Lohr J, Guenther JM, Engel AM. Deciphering mesenteric venous thrombosis: imaging and treatment. Vasc Endovascular Surg 2005; 39:473.</a></li><li><a class="nounderline abstract_t">Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg 2005; 29:204.</a></li><li><a class="nounderline abstract_t">Plessier A, Murad SD, Hernandez-Guerra M, et al. A prospective multicentric follow-up study on 105 patients with acute portal vein thrombosis (PVT): results from the European Network for Vascular Disorders of the LIver (EN-Vie). Hepatology 2007; 46:310A.</a></li><li><a class="nounderline abstract_t">Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345:1683.</a></li></ol></div><div id="topicVersionRevision">Topic 3579 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960436" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895720" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219529" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766546" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Portal vein thrombosis, revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6385690" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Portal venous thrombosis: correlative analysis of sonography, CT and angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136689" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Imaging and radiological interventions of portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326882" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : CT of portal venous occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35677518" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Portal Vein Thrombosis in Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816536" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Portal vein evaluation with US: comparison to angiography combined with CT arterial portography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881793" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Portal thrombosis: dynamic CT features and course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032150" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10887231" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883708" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sonographic features of portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853809" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnosis of portal vein thrombosis: value of color Doppler imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30771355" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12014935" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessment of portal venous system patency in the liver transplant candidate: a prospective study comparing ultrasound, microbubble-enhanced colour Doppler ultrasound, with arteriography and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20440775" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057522" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benign and malignant portal vein thrombosis: differentiation by CT characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24907725" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846289" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Successful treatment of acute portal vein thrombosis with rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313630" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29886103" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078681" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088782" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725062" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821530" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081529" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958760" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic factors in noncirrhotic patients with splanchnic vein thromboses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17697371" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Portal vein thrombosis; risk factors, clinical presentation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22289875" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19304336" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High levels of factor VIII and risk of extra-hepatic portal vein obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892458" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9583875" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8963056" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Acute portal vein thrombosis in liver cirrhosis: successful recanalization with the use of a portosystemic shunt (TIPS)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671772" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : [Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21882035" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of acute non-cirrhotic and non-malignant portal vein thrombosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872320" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942542" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The role of anticoagulation in pylephlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924535" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical features, diagnosis and outcome of acute portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9587554" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : [Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382268" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Deciphering mesenteric venous thrombosis: imaging and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15649730" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A prospective multicentric follow-up study on 105 patients with acute portal vein thrombosis (PVT): results from the European Network for Vascular Disorders of the LIver (EN-Vie)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759648" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mesenteric venous thrombosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
